| Do science and money go together? The case of the French biotech industry R Durand, O Bruyaka, V Mangematin Strategic Management Journal 29 (12), 1281-1299, 2008 | 98 | 2008 |
| Sell-off or shut-down? Alliance portfolio diversity and two types of high tech firms’ exit O Bruyaka, R Durand Strategic Organization 10 (1), 7-30, 2012 | 45 | 2012 |
| Strategic corporate social responsibility and orphan drug development: Insights from the US and the EU biopharmaceutical industry O Bruyaka, HK Zeitzmann, I Chalamon, RE Wokutch, P Thakur Journal of Business Ethics 117 (1), 45-65, 2013 | 39 | 2013 |
| Run away or stick together? The impact of organization-specific adverse events on alliance partner defection O Bruyaka, D Philippe, X Castañer Academy of Management Review 43 (3), 445-469, 2018 | 33 | 2018 |
| Flow signals: Evidence from patent and alliance portfolios in the US biopharmaceutical industry T Caner, O Bruyaka, JE Prescott Journal of Management Studies 55 (2), 232-264, 2018 | 25 | 2018 |
| Better at home, abroad, or both? How Chinese firms use ambidextrous internationalization strategies to drive innovation C Prange, O Bruyaka, R Tung, GK Stahl Cross Cultural & Strategic Management, 2016 | 22 | 2016 |
| Impact of HIPAA provisions on the stock market value of healthcare institutions, and information security and other information technology firms L Khansa, DF Cook, T James, O Bruyaka computers & security 31 (6), 750-770, 2012 | 22 | 2012 |
| Using network-based text analysis to analyze trends in Microsoft's security innovations TL James, L Khansa, DF Cook, O Bruyaka, KB Keeling computers & security 36, 49-67, 2013 | 10 | 2013 |
| Co-evolutionary perspective on sourcing portfolios: Examining sourcing choices for clinical trials of bio-pharmaceutical firms P Thakur-Wernz, O Bruyaka Management International Review 57 (6), 909-946, 2017 | 9 | 2017 |
| ALLIANCE PARTNER DIVERSITY AND BIOTECH FIRMS'EXIT: DIFFERING EFFECTS ON DISSOLUION VS. DIVESTMENT. OP BRUYAKA Academy of management proceedings 2008 (1), 1-6, 2008 | 9 | 2008 |
| Investigating the transformation and transition processes between dynamic capabilities: evidence from DHL C Prange, O Bruyaka, K Marmenout Organization Studies 39 (11), 1547-1573, 2018 | 8 | 2018 |
| Antecedents and relative performance of sourcing choices for new product development projects P Thakur-Wernz, O Bruyaka, F Contractor Technovation 90, 102097, 2020 | 5 | 2020 |
| Performance de la RD O Bruyaka Revue française de gestion, 23-36, 2005 | 4 | 2005 |
| Reexamining CEO duality: The surprisingly problematic issues of conceptualization and measurement S Gove, M Junkunc, O Bruyaka, LR Kabbach de Castro, ... Corporate Governance: An International Review 25 (6), 411-427, 2017 | 3 | 2017 |
| Strategic complementarities in M&As: evidence from the US information retrieval services industry O Bruyaka, T James, DF Cook, R Barkhi Information Technology and Management 16 (2), 97-116, 2015 | 3 | 2015 |
| Overcoming innovation barriers: Alliance portfolio characteristics and technological innovations MK Srivastava, O Bruyaka, DR Gnyawali | 2 | 2013 |
| Tapping Regional And Corporate Scientific Knowledge For Innovation: The Moderating Role Of Scientific Knowledge Duration O Bruyaka, FX Ji, LF Tegarden, DE Hatfield, WB Lamb International Journal of Innovation Management 19 (01), 1550001, 2015 | 1 | 2015 |
| Patent and alliance portfolio flow signals: Evidence from the US biopharmaceutical industry T Caner, O Bruyaka, JE Prescott Academy of Management Proceedings 2015 (1), 10099, 2015 | 1 | 2015 |
| Run Away or Stick Together? Predicting Alliance Termination in Light of Adverse Events OP Bruyaka, D Philippe Academy of Management Proceedings 2012 (1), 12713, 2012 | 1 | 2012 |
| Alliance portfolio diversity and market scope: direct and interaction effects on biotech firms' exit O Bruyaka HAL Post-Print, 2008 | 1 | 2008 |
